CN103621871B - 一种复合氨基酸保健品及其制备方法 - Google Patents
一种复合氨基酸保健品及其制备方法 Download PDFInfo
- Publication number
- CN103621871B CN103621871B CN201310612100.5A CN201310612100A CN103621871B CN 103621871 B CN103621871 B CN 103621871B CN 201310612100 A CN201310612100 A CN 201310612100A CN 103621871 B CN103621871 B CN 103621871B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- amino acid
- health
- parts
- care product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Compound amino acid Chemical class 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 40
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 30
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 18
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 14
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 14
- 239000011718 vitamin C Substances 0.000 claims abstract description 14
- 229930091371 Fructose Natural products 0.000 claims abstract description 13
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 13
- 239000005715 Fructose Substances 0.000 claims abstract description 13
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 235000001014 amino acid Nutrition 0.000 claims description 26
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 9
- 235000019197 fats Nutrition 0.000 abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract description 2
- 235000019158 vitamin B6 Nutrition 0.000 abstract description 2
- 239000011726 vitamin B6 Substances 0.000 abstract description 2
- 229940011671 vitamin b6 Drugs 0.000 abstract description 2
- 229940024606 amino acid Drugs 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract 1
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract 1
- 229930003471 Vitamin B2 Natural products 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 abstract 1
- 229960002477 riboflavin Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 235000019163 vitamin B12 Nutrition 0.000 abstract 1
- 239000011715 vitamin B12 Substances 0.000 abstract 1
- 235000019164 vitamin B2 Nutrition 0.000 abstract 1
- 239000011716 vitamin B2 Substances 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 description 22
- 235000013343 vitamin Nutrition 0.000 description 22
- 239000011782 vitamin Substances 0.000 description 22
- 229940088594 vitamin Drugs 0.000 description 22
- 150000003722 vitamin derivatives Chemical class 0.000 description 20
- 102000040350 B family Human genes 0.000 description 15
- 108091072128 B family Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000004060 metabolic process Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000003087 glucogenic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000024466 platelet membrane fluidity Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种复合氨基酸保健品，属保健类食品领域，包括如下重量份数的原料：L-丙氨酸2.5-3、L-谷氨酸4.5-5、果糖10、低聚异麦芽糖15-20、维生素C0.002-0.003、维生素B10.0006-0.0008、维生素B20.0002-0.0004、维生素B60.0003-0.0004、维生素B120.0001、α-亚麻酸8-10。同时提供复合氨基酸保健品的制备方法。本发明配方科学，各组分之间具有明显的相互协同作用，具有提高人体免疫力，降低血脂，预防心脑血管疾病，解除疲劳，增强体力，保护视力，有益智力，延缓衰老，解酒护肝等作用。
Description
技术领域
本发明涉及一种复合氨基酸保健品，属于保健类食品领域。
背景技术
蛋白质是生命的物质基础，氨基酸是合成蛋白质的基本单位，是人体生命活动所必需的基本物质，其中丙氨酸在人体内的代谢产物为泛酸，泛酸不仅可以增加人体抵抗力，还能促进体内酒精的代谢，保护肝脏，谷氨酸在脑和肌肉内合成谷氨酰胺，运输到肝和肾脏后再分解成氨和谷氨酸，从而进行解毒，另外谷氨酸还有稳定中枢神经的作用；维生素是一类维持机体正常代谢和身体健康必不可缺少的物质，且大部分在人体内不能合成，或合成量不足，只靠日常的食物供给难以满足人体所需，需要从其他途径补充。
目前，市场上生产销售的复合氨基酸类保健品中，复合氨基酸冲剂比较常见，但产品存在异味严重，口感差，市场接受度低现象，不利于复合氨基酸应用于食品行业。中国发明CN1045390C《复合氨基酸冲剂》采用甘草、黄芪、五味子、陈皮等中药制成流膏，再与复合氨基酸粉等原料配合，最后制成一种冲剂，虽然一定程度上改善了口感，但是中药特殊的味道，仍然不易为普通消费者接受，而且中药的适用存在个体差异性问题，因而不利于市场推广。
中国发明CN1117824A公开了一种《复合氨基酸饮料》公开了一种含有复合氨基酸的营养保健型饮料，以碳酸饮料、果汁饮料或蔬菜汁饮料为主料，虽然解决了异味大、口感差的缺陷，但是营养保健功能并不突出。
发明内容
本发明的目的在于克服目前技术上的缺陷，提供一种吸收效果好、口感良好、质量稳定的复合氨基酸保健品，包括如下重量份数的原料：L-丙氨酸2.5-3、L-谷氨酸4.5-5、果糖10、低聚异麦芽糖15-20、维生素C0.002-0.003、维生素B10.0006-0.0008、维生素B20.0002-0.0004、维生素B60.0003-0.0004、维生素B120.0001、α-亚麻酸8-10。
本发明的另一目的是提供复合氨基酸保健品的制备方法，主要特征是将L-丙氨酸、L-谷氨酸、低聚异麦芽糖、果糖、α-亚麻酸、B族维生素、维生素C等按不同比例混合制得，本发明效果稳定，适合大规模生产。
L-丙氨酸
L-丙氨酸是是血液中含量最多的一种氨基酸，在葡萄糖-丙氨酸循环中，保持低血氨水平，是血中氮的优良运输工具，又是一种有效生糖氨基酸。维生素B6、泛酸钙和其他有机化合物的合成通常都需要丙氨酸的参与。
L-谷氨酸：
L－谷氨酸，是一种酸性氨基酸。分子内含两个羧基，化学名称为α-氨基戊二酸。谷氨酸在生物体内的蛋白质代谢过程中占重要地位，参与许多重要化学反应。医学上谷氨酸主要用于治疗肝性昏迷，还用于改善儿童智力发育。谷氨酸是生物机体内氮代谢的基本氨基酸之一，在代谢上具有重要意义。L－谷氨酸是蛋白质的主要构成成分，它即是蛋白质或肽的结构氨基酸之一，又是游离氨基酸。
果糖：
人们饮酒后,洒精很快便被吸收，进行氧化分解，整个反应过程耗氧多，耗能巨大，时间长，肝脏负担重。在肝脏解酒过程中，会发生酒精性低血糖和肝细胞的缺氧损伤，而酒精性低血糖是诱发加剧糖尿病的重要因素。在解酒制品中加入果糖，可以发挥果糖的多种功效。果糖吸收代谢迅速，可及时弥补酒精性的低血糖。果糖的代谢过程路径短，耗能低，不产生乳酸，在肝脏缺氧情况下仍可代谢，肝脏负担轻。果糖能促进体内醇的分解，抑制蛋白质消耗，减少毒性最大的中间产物乙醛的停留时间。果糖还可减少酒精对肝细胞的缺氧损伤，减少缺氧肝细胞的死亡，在缺氧消除后及时恢复肝细胞的代谢能力。
果糖广泛应用于食品、保健品生产中。它不仅仅是解决甜度问题,更主要是改善制品性能，增进风味口感，提高产品档次。同时，果糖吸收代谢快，可迅速给机体补充能量，不但可增加体能和耐力，还可保持体力，迅速消除疲劳。
另外，由于结晶果糖溶解性良好，利用这个特性可开发出各种粉末饮料，这样即发挥了粉末饮料易运输携带的方便性，又具有液体饮料口感好，产品多样化的特点。
低聚异麦芽糖
低聚异麦芽糖促进肠道益生菌的增殖，促进B族维生素的合成及钙的吸收，从而提高机体免疫力
维生素C
维生素C又称抗坏血酸，是一种水溶性维生素，容易不断从人体中流失。人体不能制造维生素C，因此必须每天从含维生素C的食物中摄取来满足身体需要。在所有维生素中，维生素C是人体每天需要量最多的维生素，主要是因为维生素C在贮存、加工和烹调时容易被破坏，而污染、酗酒、服药、节食、吸烟和身体活动都会消耗维生素C。
维生素C的保健作用主要包括以下方面：
1.增强免疫力，预防感冒及病毒与细菌的感染；
2.提高智力，促进胎儿生长发育，降低孕妇分娩危险；
3.天然的抗氧化剂，天然的退烧剂；天然的轻泻剂，改善便秘；
4.抗压力，提高细胞活力，延缓机体衰老，增强肌体对外界环境的抗应激能力；
5.有抗氧化作用，减少自由基对身体的损害；美白肌肤，延缓黑色素生成，减少皱纹；
6.改善脂肪和类脂特别是胆固醇的代谢，降低胆固醇，预防动脉硬化，减少血管中血栓的形成，对预防高血压有一定作用；
7.维持胶原组织，帮助肌肤和骨骼的胶原蛋白生成，有助于巩固结缔组织，维持骨密度，保护骨骼、牙齿，治疗受伤、烧伤、烫伤、牙床出血；抑制炎症，加速术后伤口愈合；
8.抗坏血病，降低毛细血管通透性，促进血液凝聚；
9.改善肝功能，预防癌症和白内障；
10.改善铁、钙和叶酸的利用，预防及改善贫血。
B族维生素
维生素B1被称为精神性的维生素，这是因为维生素B1对神经组织和精神状态有良好的影响。维生素B2进入人体后磷酸化，转变成磷酸核黄素及黄素腺嘌呤二核苷酸，与蛋白质结合成为一种调节氧化-还原过程的脱氢酶。脱氢酶是维持组织细胞呼吸的重要物质。缺乏它，体内的物质就会出现代谢紊乱。维生素B6是机体内许多重要酶系统的辅酶，参与氨基酸的脱羧作用、色氨酸的合成、含硫氨基酸的代谢和不饱和脂肪酸的代谢等生理过程，是动物正常发育、细菌和酵母繁殖所必需的营养成分。维生素B12对身体制造红血球和保持免疫系统的功能是必需的。一般食物中的维生素B12很难被人体吸收，而且很容易通过尿排除体外。老人和酗酒者尤其容易缺乏维生素B12。
B族维生素是维持人体正常机能与代谢活动不可或缺的水溶性维生素，人体无法自行制造合成，必须额外补充。B族维生素广泛存在于米糠、麸皮、酵母、动物的肝脏、粗粮蔬菜等食物中。但VB是水溶性维生素，它怕光、怕水、怕热、怕氧化（多在80度温度下被破坏），通常的饮食习惯很难将其利用。这些B族维生素是推动体内代谢，把糖、脂肪、蛋白质等转化成热量时不可缺少的物质。如果缺少维生素B，则细胞功能马上降低，引起代谢障碍，这时人体会出现怠滞和食欲不振。相反喝酒过多等导致肝脏损害，在许多场合下是和维生素B缺乏症并行的。B族维生素有很多共同的方面，比如它们都是水溶性的，多余的B族维生素不会贮藏于体内，而会完全排出体外。所以，B族维生素必须每天补充。
B族维生素之间具有很强的协同作用——也就是说，按适宜比例摄取全部B族的维生素，要比分别摄取效果更好。例如，维生素B1.B2.B6联合应用治疗维生素B缺乏症，有协同作用，疗效增强。维生素B6与维生素B12合用可改善肠道对药物的耐受性，促进维生素B12的吸收，这可能与维生素B能促进“内因子”分泌有关。如果B1.B2.B6摄取比率不适宜，则B族维生素的保健效果会大打折扣。
此外，研究人员普遍认为，长期饮酒会影响多种B族维生素的摄入、吸收及在体内的代谢过程，因而会增加人体对这些营养物质的需要量。
α-亚麻酸
α-亚麻酸（alpha-Linolenic acid，简称ALA)可防止凝血、改善血管的柔韧性、并且可以防治心律不齐。ALA与心血管病死亡率，包括心脏病和中风，有强烈的相关性。大量的基础研究、流行病学调查、动物试验及临床观察表明，α-亚麻酸具有以下方面的生理功效：
1.预防心脑血管病：α-亚麻酸可以改变血小板膜流动性，从而改变血小板对刺激的反应性及血小板表面受体的数目，能有效防止血栓的形成。
2.降血脂：α-亚麻酸的代谢产物对血脂代谢有温和的调节作用，能促进血浆低密度脂蛋白（LDL）向高密度脂蛋白（HDL）的转化，使低密度脂蛋白（LDL）降低，高密度脂蛋白（HDL）升高，从而达到降低血脂，防止动脉粥样硬化的目的。
3.降低临界性高血压：α-亚麻酸的代谢产物可以扩张血管，增强血管弹性，从而起到降压作用。
4.抑制癌症的发生和转移：α-亚麻酸的代谢产物可以直接减少致癌细胞生成数量，同时削弱血小板的凝集作用，抑制二烯前列腺素的生成，恢复及提高人体的免疫系统功能，从而能有效地防止癌症形成以及抑制其转移
5.抑制过敏反应、抗炎作用：α-亚麻酸对过敏反应及炎症有抑制效果。临床研究得出，牛皮癣的发病机理主要由花生四烯酸代谢紊乱所致，而摄入一定量的EPA后症状得以减轻。大量的动物实验证明，体质的过敏反应亢进是由α-亚麻酸摄入不足引起的。
6.抑制衰老：服用α-亚麻酸后，体内谷胱甘肽过氧化物酶（GSH-Px）及SOD活性增加,自由基代谢产物丙二醛（MDA）的生成减少，揭示α-亚麻酸有抗衰老作用。
7.增强智力：健全的大脑绝对不可缺少脂肪酸，特别是α-亚麻酸，脂肪酸为大脑提供所需的能量，人脑之所以能从事高度复杂的工作，离不开高质量的脂肪酸。18个碳原子的α-亚麻酸可以进一步延伸碳链，增加双键个数，生成EPA和DHA。DHA在脑神经细胞中大量集存，是大脑形成和智商开发的必需物质。
8.保护视力：视网膜中特别是视细胞外DHA特别多，如果缺乏，视力就会下降，视网膜反射能力恢复时间延长。而α-亚麻酸代谢产物DHA，可以提高和保护视力。
本发明产品推荐服用量：成人，按60kg体重计,建议按产品包装建议量，每日一次，饮酒后需加服一次。
有益效果
本发明配方科学，各组分之间具有明显的相互协同作用，低聚异麦芽糖促进肠道益生菌的增殖，促进B族维生素的合成及钙的吸收，从而提高机体免疫力，B族维生素之间也具有很强的协同作用，适宜的比例能够提高B族维生素的整体利用效果，各组分协同配合可以帮助维持心脏、神经系统功能，维持消化系统及皮肤的健康，增强体力，保护视力，有益智力，延缓衰老。具有提高人体免疫力、降低血脂、预防心脑血管疾病、解除疲劳、解酒护肝等作用，可直接食用或与牛奶、饮料、咖啡、茶等混匀饮用。
具体实施方式
以下通过具体实施例对本发明做更详细的说明，以帮助本领域技术人员更好地理解本发明的技术内容。具体实施方式应理解为对本发明的进一步说明，而不应理解为对本发明保护范围的限定。
实施例1粉末状冲剂的制备
复合氨基酸冲剂各组分配比：
L-丙氨酸25kg、L-谷氨酸50k g、果糖100kg、低聚异麦芽糖150kg、维生素C0.03kg、维生素B10.008kg、维生素B20.002kg、维生素B60.003kg、维生素B120.001kg、α-亚麻酸80kg，用消毒过的纯水定容至1000L，然后经过喷雾干燥得到固体粉末状复合氨基酸，装入非透明食品包装袋中，即得到成品。
实施例2颗粒状冲剂的制备
复合氨基酸冲剂各组分配比：
L-丙氨酸300g、L-谷氨酸450g、果糖1.0Kg、低聚异麦芽糖2.0Kg、维生素C0.2g、维生素B10.06g、维生素B20.04g、维生素B60.04g、维生素B120.01g、维生素E0.05g、α-亚麻酸1000g，用无菌纯水定容至10L，以3%的聚维酮乙醇溶液作为粘合剂，经过造粒技术得到颗粒状复合氨基酸，装入非透明食品包装袋中即可。
实施例3复合氨基酸软胶囊的制备
L-丙氨酸300g、L-谷氨酸450g、果糖1.0Kg、低聚异麦芽糖2.0Kg、维生素C0.2g、维生素B10.06g、维生素B20.04g、维生素B60.04g、维生素B120.01g、α-亚麻酸1000g、色拉油3.0kg，用无菌纯水定容至10L，搅拌均匀后灌装制成软胶囊，每粒胶囊总重500毫克。
Claims (2)
1.一种复合氨基酸保健品，由如下重量份数的原料组成：L-丙氨酸2.5-3、L-谷氨酸4.5-5、果糖10、低聚异麦芽糖15-20、维生素C 0.002-0.003、维生素B1 0.0006-0.0008、维生素B20.0002-0.0004、维生素B6 0.0003-0.0004、维生素B12 0.0001、α-亚麻酸8-10。
2.制备如权利要求1所述复合氨基酸保健品的方法，将原料按不同比例混合制得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310612100.5A CN103621871B (zh) | 2013-11-27 | 2013-11-27 | 一种复合氨基酸保健品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310612100.5A CN103621871B (zh) | 2013-11-27 | 2013-11-27 | 一种复合氨基酸保健品及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103621871A CN103621871A (zh) | 2014-03-12 |
| CN103621871B true CN103621871B (zh) | 2015-04-29 |
Family
ID=50203603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310612100.5A Active CN103621871B (zh) | 2013-11-27 | 2013-11-27 | 一种复合氨基酸保健品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103621871B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107212218A (zh) * | 2017-06-29 | 2017-09-29 | 湖北航天杜勒制药有限公司 | 一种氨基酸饮品 |
| CN109198572A (zh) * | 2017-07-04 | 2019-01-15 | 铭友科技有限公司 | 褐藻类萃取物调味料的制造方法及用该方法制成的调味料 |
| CN110433195A (zh) * | 2018-05-05 | 2019-11-12 | 西双版纳华坤生物科技有限责任公司 | 一种物质在解酒护肝上的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101478891A (zh) * | 2006-06-27 | 2009-07-08 | Shs国际有限公司 | 营养制剂 |
| CN102309006A (zh) * | 2011-09-01 | 2012-01-11 | 郭景龙 | 一种具有保健作用的食品 |
-
2013
- 2013-11-27 CN CN201310612100.5A patent/CN103621871B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101478891A (zh) * | 2006-06-27 | 2009-07-08 | Shs国际有限公司 | 营养制剂 |
| CN102309006A (zh) * | 2011-09-01 | 2012-01-11 | 郭景龙 | 一种具有保健作用的食品 |
Non-Patent Citations (1)
| Title |
|---|
| 氨基酸保健品最新应用进展初探;李静;《天津科技》;20101231(第1期);72-73 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103621871A (zh) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
| CN100502692C (zh) | 一种体力恢复保健食品及其制备方法 | |
| CN104509919A (zh) | 一种功能性营养素饮料 | |
| CN101473953A (zh) | 净血排毒组合食品及其加工方法和应用 | |
| TWI721248B (zh) | 提高耐力表現之抗疲勞組合物 | |
| CN104855967A (zh) | 肥胖、减脂手术非全营养配方食品 | |
| CN104187916B (zh) | 一种绿色环保饮品、食用酵素及其制备方法 | |
| CN102224891A (zh) | 一种糖醇蜂蜜苹果酱及其制备方法 | |
| CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
| CN102048225B (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
| CN104855994A (zh) | 肾病非全营养配方食品 | |
| CN105768108A (zh) | 一种适用于肿瘤患者服用的特膳食品 | |
| CN108013299A (zh) | 补充体能饮料 | |
| CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
| CN103815227A (zh) | 一种复合维生素红糖组合物及其应用 | |
| CN107969541A (zh) | 一种心肌肽压片糖果 | |
| CN104839695A (zh) | 炎性肠病非全营养配方食品 | |
| CN104856000A (zh) | 失眠非全营养配方食品 | |
| CN104839698A (zh) | 心血管疾病非全营养配方食品 | |
| CN103989044A (zh) | 一种配方红糖组合物及其应用 | |
| JP2006197911A (ja) | 蜂の子利用の健康食品。 | |
| KR101642176B1 (ko) | 성장촉진 조성물 | |
| CN102511875A (zh) | 一种适合术后人群饮用的红枣浓浆 | |
| CN104839704A (zh) | 壮阳非全营养配方食品 | |
| CN108851037A (zh) | 一种肾病综合征全营养食品的制备方法及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |